CXCR2 and prostate cancer: We reasoned that CXCR2 chemokines released by human prostate cancer cells sculpt systemic myeloid inflammation, and that targeting CXCR2 would decrease deleterious myeloid inflammation, reverse ARSI resistance and impart clinical benefit in some patients with mCRPC.